Vaccines, Blood & Biologics

Regulatory Harmonization and Convergence

The term “regulatory harmonization” can have different definitions depending on the context of its usage. One definition that is applicable to those efforts CBER is involved with is: the process by which technical guidelines are developed to be uniform across participating authorities. “Regulatory convergence,” on the other hand, represents a process whereby the regulatory requirements across countries or regions become more similar or “aligned” over time as a result of the gradual adoption of internationally recognized technical guidance documents, standards and scientific principles, common or similar practices and procedures, or adoption of regulatory mechanisms that might be specific to a local legal context but that align with shared principles to achieve a common public health goal. It does not necessarily represent the harmonization of laws and regulations, which is not a prerequisite for allowing the alignment of technical requirements and greater regulatory cooperation. The Agency engages in a range of explicit harmonization initiatives as well as convergence activities, a number of which include the participation of CBER.

CBER Harmonization Program Activities

Asia-Pacific Economic Cooperation Life Sciences Innovation Forum Regulatory Harmonization Steering Committee

The Asia-Pacific Economic Cooperation (APEC) organization is a multilateral, voluntary collective of economies that border the Pacific. APEC promotes trade and sustainable economic growth through policy alignment and technical cooperation. APEC undertakes its work through an array of dedicated subject matter fora, which includes the Life Sciences Innovation Forum (LSIF). The primary goal of the LSIF “is to bring together representatives of the government, private sector and academia to promote life-sciences innovation in support of human health in the region.”  In 2008, the Regulatory Harmonization Steering Committee (RHSC) was created under the authority of the LSIF in order to promote a strategic and coordinated approach to medical product regulatory harmonization/convergence and capacity building efforts within the APEC region. The RHSC has developed a Strategic Framework that identifies priority work areas and implementation roadmaps which promote greater convergence in the regulation of medical products, which includes training as an important component. FDA CBER joins the Center for Drug Evaluation and Research and the Center for Devices and Radiological Health in participating in the RHSC and its working groups. FDA CBER experts contribute to the following priority work areas: Supply Chain Integrity and Product Quality, Pharmacovigilance, Good Review Practices, Multi-regional Clinical Trials, Good Clinical Practice Inspection, Cell and Tissue-based Therapeutic Products, and Biotherapeutic Products.

International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use

The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) was created in 1990 and stands as the seminal initiative in the domain of regulatory harmonization for medical products. As of 2015, it is an initiative in transition with significant changes expected. Notably, it is expected to become a legal entity in the form of a Swiss non-profit association with an associated name change to the International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Nevertheless, its primary goal, whether the past, present or future, is the development of harmonized guidelines through a process of scientific consensus by regulatory and industry experts. Its overarching goal is to ensure that safe, effective and high quality medicines are developed, and then registered, in the most resource-efficient manner. Updated information will be posted on this web page once the anticipated transition is completed.

International Medical Device Regulators Forum

The International Medical Device Regulators Forum (IMDRF) was conceived in February 2011 as a forum to discuss future directions in medical device regulatory harmonization. It is a voluntary group of medical device regulators from around the world who have come together to build on the strong foundational work of the Global Harmonization Task Force on Medical Devices (GHTF), and to accelerate international medical device regulatory harmonization and convergence. The current members as of 2015 are: Australia, Brazil, Canada, China, Europe, Japan, Russia, and the U.S. The World Health Organization and the APEC LSIF Regulatory Harmonization Steering Committee are Official Observers. The Asian Harmonization Working Party and the Pan American Health Organization are IMDRF Affiliate Organizations.

IMDRF is primarily an engagement of FDA’s Center for Devices and Radiological Health (CDRH), however because CBER also regulates certain devices, it participates through CDRH to assure our interests are represented. CBER regulates devices such as cell separation devices, blood collection containers and HIV screening tests that are used to prepare blood and cell products or to ensure the safety of the blood supply.

International Pharmaceutical Regulators Forum

The International Pharmaceutical Regulators Forum (IPRF) is a voluntary collective of regulatory authorities and Regional Harmonization Initiatives originally created in the form of a Regulators Forum to serve as a safe harbor for discussion and promotion of harmonization among its members. The purpose of the IPRF is to create an environment for members to exchange information on issues of mutual concern and to undertake targeted regulatory cooperation. The dedicated venue seeks to maximize potential efficiencies in addressing the increasingly complex global context of medicines regulation, to facilitate the implementation of ICH and other internationally harmonized technical guidelines for pharmaceuticals for human use and to contribute to the coordination of a range of international efforts related to the regulation of medicinal products for human use. As of 2015, five working groups have been established specific to: Gene Therapies, Cell Therapies, Good Clinical Practices (ICH E6), Biosimilars, and Nanomedicines. CBER joins the Center for Drugs Evaluation and Research (CDER) as members of the IPRF.

Pan American Network for Drug Regulatory Harmonization

The Pan American Network for Drug Regulatory Harmonization (PANDRH) is an initiative of the National Regulatory Authorities of the region and the Pan American Health Organization that supports the processes of regulatory convergence/harmonization in the Americas, within the framework of national and sub-regional realities, needs, laws and policies related to health. The PANDRH comprises:

The Pan American Conference on Drug Regulatory Harmonization, the Steering Committee, the Advisory Council and the Technical Groups in as many areas as defined by the Conference and the Secretariat to be a priority. Its mission is to advance regulatory convergence in the arena of health products covering aspects of quality, safety, effectiveness and rational use of health products, and the strengthening of the capacities of the National Regulatory Authorities (NRAs) in the region of the Americas, based on the needs of the population to have access to quality health products in accordance with the progress of science and technology within the context of national and sub-regional realities. CBER participates in partnership with the CDER, the CDRH, the Office of Regulatory Affairs and the Office of International Programs in the Office of the Commissioner.

Return to CBER's International Activities Home Page

Page Last Updated: 09/29/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English